University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr — Philadelphia, Pennsylvania

University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr is a clinical research site located in Philadelphia, Pennsylvania, United States 19104 4283.

Crixeo Health Trust Score: 44/100 (POOR). This profile has not yet been claimed by the site owner.

University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr has participated in 1 clinical trials.

Therapeutic areas: Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD).

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 44/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr?

University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr has a Crixeo Trust Score of 44/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr conducted?

University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr has 1 clinical trials on record. Their work covers Acute Myeloid Leukemia (AML) With, FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD).

Is University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr accredited by Crixeo Health?

University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.